A Phase 2/3 interventional study of Setmelanotide in Obesity Associated With Defects in Leptin-melanocortin Pathway, sponsored by Rhythm Pharmaceuticals, Inc.. Completed at 27 sites in 8 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2025-05-31.
Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing setmelanotide in Obesity — 1 open to participants now, 2 under way, none of them phase 3. setmelanotide · Obesity.
Among the 16 studies testing setmelanotide in Obesity, this one is the 3rd largest by enrollment, is one of 3 that started in 2018, is the only one in phase 2/3, and was the 9th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →1 of the 16 studies testing setmelanotide in Obesity is open now, in 1 country. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
By country, each count listing its studies:
setmelanotide: first FDA approval 2020 (IMCIVREE), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 7
First in 2012; this study’s year is marked. 3 started in 2018.
This study's enrollment of 205 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 34 across the 16 interventional studies. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 16 have an industry lead sponsor. The 2 most frequent:
Rhythm Pharmaceuticals, Inc. is the lead sponsor of 29 studies on the registry; 2 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 15 (79%) have results posted.
19 studies in Obesity by Rhythm Pharmaceuticals, Inc.: none open now, 2 under way, none of them phase 3. Of 16 finished, 10 (63%) have results posted.
Among the 19 studies in Obesity by Rhythm Pharmaceuticals, Inc., this one is the 3rd largest by enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2018, is the only one in phase 2/3, and was the 9th registered.
Rhythm Pharmaceuticals, Inc.’s Obesity studies by the year they started, since 2012.
1 of the studies testing setmelanotide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07496463Massachusetts General HospitalSetmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a) | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies testing setmelanotide in Obesity, from their registry updates:
Among Rhythm Pharmaceuticals, Inc.’s 19 in Obesity:
This tab as a report to print or save as PDF → With an account.
This was a long-term extension trial to study the safety and tolerability of continued setmelanotide treatment in participants who had completed a previous clinical trial on treatment with setmelanotide for obesity associated with genetic defects upstream of the Melanocortin-4 (MC4) receptor in the leptin-melanocortin pathway.
The primary objectives of this extension trial were to explore the long-term safety and tolerability of setmelanotide for up to 7 years or until drug was otherwise available through authorized use. Participants entered this protocol immediately upon completion of their index protocol such that dosing of setmelanotide continued without gaps in therapy.
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received setmelanotide at the same starting dose as received in the index trials as a Subcutaneous (SC) injection once daily for up to 5.6 years in this extension trial.
Drug: Setmelanotide
Once daily subcutaneous injection
Also known as: RM-493
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A TEAE was defined as any AE that began or worsened in intensity on or after the date of the first administration of study drug.
Time frame: From first dose up to 5.6 years
Participants from previous index trials (RM-493-011\[NCT02507492\], RM-493-012 \[NCT02896192\], RM-493-014\[NCT03013543\], RM-493-015 \[NCT03287960\], RM-493-023 \[NCT03746522\], RM-493-030 \[NCT04725240\], RM-493-034 \[NCT04963231\] with rare genetic, syndromic, or acquired diseases of obesity upstream of the Melanocortin-4 receptor (MC4R) in the melanocortin-leptin pathway and other abnormalities of the MC4R pathway and wished to continue with setmelanotide treatment were enrolled in this extension trial.
| Milestone | Setmelanotide |
|---|---|
| Started | 205 |
| Completed | 89 |
| Not completed | 116 |
| Withdrew: Adverse event | 6 |
| Withdrew: Lack of efficacy | 18 |
| Withdrew: Lost to follow-up | 5 |
| Withdrew: Non-compliance with study drug | 4 |
| Withdrew: Physician decision | 6 |
| Withdrew: Pregnancy | 1 |
| Withdrew: Discontinued by sponsor | 40 |
| Withdrew: Withdrawal by parent/guardian | 6 |
| Withdrew: Withdrawal by subject | 24 |
| Withdrew: Miscellaneous | 6 |
An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A TEAE was defined as any AE that began or worsened in intensity on or after the date of the first administration of study drug.
| Participants | Setmelanotide |
|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 198 |
Collected over From first dose up to 5.6 years. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Setmelanotide | 0/205 (0%) | 27/205 (13.2%) | 198/205 (96.6%) |
| Event | Setmelanotide |
|---|---|
| Adrenocortical insufficiency acuteEndocrine disorders | 3/205 |
| Suicidal ideationPsychiatric disorders | 2/205 |
| SeizureNervous system disorders | 2/205 |
| CraniopharyngiomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/205 |
| Endometrial cancer stage INeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/205 |
| Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/205 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/205 |
| Renal neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/205 |
| Gastroenteritis Escherichia coliInfections and infestations | 1/205 |
| Pilonidal diseaseInfections and infestations | 1/205 |
| Event | Setmelanotide |
|---|---|
| Skin HyperpigmentationSkin and subcutaneous tissue disorders | 110/205 |
| Covid-19Infections and infestations | 60/205 |
| HeadacheNervous system disorders | 60/205 |
| Injection Site ErythemaGeneral disorders | 43/205 |
| Melanocytic NaevusNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 41/205 |
| Injection Site PruritusGeneral disorders | 38/205 |
| Upper Respiratory Tract InfectionInfections and infestations | 36/205 |
| Injection Site IndurationGeneral disorders | 35/205 |
| NasopharyngitisInfections and infestations | 32/205 |
| NauseaGastrointestinal disorders | 28/205 |
Safety Analysis Set (SAS) included all participants who received at least one dose of received at least 1 dose of setmelanotide in this extension trial.
| Age, Continuous(Years) | Setmelanotide |
|---|---|
| Mean | 22.7 ± 14.93 |
| Sex: Female, Male(Participants) | Setmelanotide |
|---|---|
| Female | 125 |
| Male | 80 |
| Race (NIH/OMB)(Participants) | Setmelanotide |
|---|---|
| American Indian or Alaska Native | 3 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 10 |
| White | 167 |
| More than one race | 0 |
| Unknown or Not Reported | 24 |
| Ethnicity (NIH/OMB)(Participants) | Setmelanotide |
|---|---|
| Hispanic or Latino | 10 |
| Not Hispanic or Latino | 171 |
| Unknown or Not Reported | 24 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2018 to primary completion in Jan 2025, 77 months.
Results were first posted in May 2025, 4 months after primary completion.
Of 36 phase 2/3 interventional studies under Obesity, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 53. This study's 77 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Setmelanotide
Rhythm Pharmaceuticals, Inc. →